|Description||BMS-687453 is a potent and selective peroxisome proliferator activated receptor PPARα agonist. with an IC50 of 10 nM for human PPARalpha and approximately 410-fold selectivity vs human PPARgamma in PPAR-GAL4 transactivation assays.|
|Synonyms||BMS-687453; BMS 687453; BMS687453.|
|Solubility||Soluble in DMSO, not in water|
|Storage||Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).|
|Shelf Life||2 years if stored properly|
CDDO Imidozolide is a synthetic triterpenoid as Nrf2 signaling activator with highly active in suppressing cellular proliferation of human leukemia and breast c...
GW-9820 is a PPAR-gamma agonist with potential antidiabetic effect.
GW-590735 is a potent and selective agonist of PPARα. Its EC50 value is 4 nM for the expression a GAL4-responsive reporter gene and at least 500-fold selectivit...
Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used for the treatment of hyperlipidaemia. It helps to lower LDL cholesterol a...
CC-618 has been found to be a PPARβ/δ antagonist that could be used to study the potential biological activity of Cys249 at some extent. IC50: 10 μM.
PPARγ is a ligand-activated nuclear receptor and was reported to plays a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation...
Naveglitazar is a Dual peroxisome proliferator-activated receptor gamma and alpha (PPARgamma and PPARalpha) agonist
PT-S58 is a full peroxisome proliferator-activated receptor (PPAR) β/δ antagonist as a derivative of GSK0660. But PT-S58 has a three-fold higher affinity for th...
A potent PPARα modulator
Saroglitazar magnesium is a dual PPAR agonist with potent predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, res...
Seladelpar is a selective peroxisome proliferator-activated receptor -δ receptor agonist. Phase II clinical trials for the treatment of Hyperlipidaemia, Hyperli...
GSK0660 is a selective PPARδ antagonist. GSK0660 blocks the effect of TNFα on the expressions of cytokines involved in leukocyte recruitment, including CCL8, CC...
Indeglitazar is a peroxisome proliferator-activated receptor (PPAR) pan-agonist. Phase II clinical trials for Type 2 diabetes mellitus was discontinued.
T0070907 was identified as a potent and selective PPARgamma antagonist. T0070907 blocked PPARgamma function in both cell-based reporter gene and adipocyte diffe...
Pioglitazone HCl is a hydrochloride salt form of pioglitazone which is a cytochrome P450 (CYP)2C8 and CYP3A4 enzymes inhibitor for CYP2C8, CYP3A4 and CYP2C9 wit...
Inolitazone is an orally bioavailable PAPR-gamma inhibitor with potential antineoplastic activity. Inolitazone binds to and activates peroxisome proliferation-a...
FH535 is a Wnt/β-catenin signaling inhibitor and also a dual PPARγ and PPARδ antagonist.
ST247 is a selective and inverse peroxisome proliferator-activated receptor (PPAR)β/δ agonist with IC 50 value of 19 nm, 10-fold more potent than GSK0660 with I...
GW9662 is a potent, irreversible and selective PPARgamma antagonist, which prevented activation of PPARgamma and inhibited growth of human mammary tumour cell ...
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity as a drug for the treatment...